Precision BioSciences, Inc.

NasdaqCM:DTIL Stock Report

Market Cap: US$214.7m

Precision BioSciences Management

Management criteria checks 3/4

Precision BioSciences' CEO is Michael Amoroso, appointed in Oct 2021, has a tenure of 4.75 years. total yearly compensation is $2.19M, comprised of 29.7% salary and 70.3% bonuses, including company stock and options. directly owns 0.94% of the company’s shares, worth $2.03M. The average tenure of the management team and the board of directors is 4.2 years and 6.5 years respectively.

Key information

Michael Amoroso

Chief executive officer

US$2.2m

Total compensation

CEO salary percentage29.73%
CEO tenure4.8yrs
CEO ownership0.9%
Management average tenure4.2yrs
Board average tenure6.5yrs

Recent management updates

Recent updates

Analysis Article • May 13

Analyst Forecasts For Precision BioSciences, Inc. (NASDAQ:DTIL) Are Surging Higher

Precision BioSciences, Inc. ( NASDAQ:DTIL ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Dec 29

Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026

Summary Precision BioSciences offers high-risk, high-reward potential, trading below cash with key HBV and DMD data catalysts expected in 2026. PBGENE-HBV targets both cccDNA and integrated HBV DNA, aiming for a functional HBV cure superior to downstream competitors. Recent $75M capital raise extends DTIL's cash runway through major readouts, supporting continued clinical development and operational flexibility. Risks include potential safety events, competitive efficacy, and uncertain milestone/royalty revenue from partnered programs. Read the full article on Seeking Alpha
Analysis Article • Aug 06

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Celebrations may be in order for Precision BioSciences, Inc. ( NASDAQ:DTIL ) shareholders, with the analysts delivering...
Analysis Article • Jun 23

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Precision BioSciences, Inc. ( NASDAQ:DTIL ) shares have had a horrible month, losing 29% after a relatively good period...
Analysis Article • Mar 14

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Dec 08

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Sep 02

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Precision BioSciences promoted Cindy Atwell to chief business officer and carried out other leadership changes. Atwell, who was serving as senior vice president of Business Development and Alliance Management, will continue to oversee the Business Development and Alliance functions with added responsibility for Project and Portfolio Management, the company said in a Sept. 2 press release. Jeff Smith, co-founder and formerly chief technology officer, was promoted to chief research officer and will assume responsibility for the management and direction of the company’s research programs and report directly to the CEO Michael Amoroso. Precision added that Derek Jantz, co-founder and chief scientific officer, will step down from the board to focus his time partnering with Amoroso in making company strategy and managing relationships with external stakeholders. Jantz departure would reduces the number of management members serving on the board, the company added. DTIL +1.27% to $1.60 premarket Sept. 1

CEO Compensation Analysis

How has Michael Amoroso's remuneration changed compared to Precision BioSciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$44m

Dec 31 2025US$2mUS$651k

-US$47m

Sep 30 2025n/an/a

-US$84m

Jun 30 2025n/an/a

-US$78m

Mar 31 2025n/an/a

-US$22m

Dec 31 2024US$4mUS$635k

US$7m

Sep 30 2024n/an/a

US$11m

Jun 30 2024n/an/a

US$16m

Mar 31 2024n/an/a

-US$20m

Dec 31 2023US$2mUS$630k

-US$43m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$31m

Mar 31 2023n/an/a

-US$59m

Dec 31 2022US$4mUS$604k

-US$73m

Sep 30 2022n/an/a

-US$76m

Jun 30 2022n/an/a

-US$93m

Mar 31 2022n/an/a

-US$40m

Dec 31 2021US$6mUS$127k

-US$31m

Compensation vs Market: Michael's total compensation ($USD2.19M) is above average for companies of similar size in the US market ($USD1.63M).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.

CEO

Michael Amoroso (48 yo)

4.8yrs
Tenure
US$2,189,467
Compensation

Mr. Michael Amoroso serves as Director, President and Chief Executive Officer of Precision BioSciences, Inc. since October 15, 2021. He served as Director at Abeona Therapeutics Inc. since March 19, 2021 u...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Amoroso
President4.8yrsUS$2.19m0.94%
$ 2.0m
John Kelly
CFO & Principal Accounting Officer5.5yrsUS$1.13m0.49%
$ 1.0m
Dario Scimeca
General Counsel & Secretary7.1yrsUS$911.64k0.22%
$ 469.7k
Jefferson Smith
Co-Founder & Chief Research Officerno dataUS$1.45m0.50%
$ 1.1m
Cassie Gorsuch
Chief Scientific Officer1.5yrsno datano data
Naresh Tanna
Chief of Staff to CEO & Head of Investor Relations1.8yrsno datano data
Juli Blanche
Chief People Officer4.2yrsno datano data
Cindy Atwell
Chief Development & Business Officerno datano datano data
Neil Leatherbury
Senior VP and Head of Chemistry3.4yrsno datano data
4.2yrs
Average Tenure
52yo
Average Age

Experienced Management: DTIL's management team is considered experienced (4.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Michael Amoroso
President4.8yrsUS$2.19m0.94%
$ 2.0m
Samuel Broder
Member of Scientific Advisory Board8.5yrsno datano data
Kenneth Anderson
Member of Scientific Advisory Board7.5yrsno datano data
Hagop M. Kantarjian
Member of Scientific Advisory Board7.5yrsno datano data
Raymond Schinazi
Member of Scientific Advisory Board7.5yrsUS$256.47kno data
Kevin Buehler
Independent Chairman6.7yrsUS$192.65k0.19%
$ 408.8k
Alan List
Clinical Consultant & Member of Scientific Advisory Board1.8yrsUS$909.97kno data
Geno Germano
Independent Director6.3yrsUS$173.90k0.17%
$ 373.4k
Shari Pire
Independent Director4.7yrsUS$162.40k0.14%
$ 291.4k
Melinda Brown
Independent Director4.2yrsUS$163.15k0.17%
$ 369.0k
Cameron Turtle
Member of Scientific Advisory Board7.5yrsno datano data
Stanley Frankel
Independent Director5.3yrsUS$334.20k0.16%
$ 336.8k
6.5yrs
Average Tenure
69yo
Average Age

Experienced Board: DTIL's board of directors are considered experienced (6.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/17 06:15
End of Day Share Price 2026/07/17 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Precision BioSciences, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Debjit ChattopadhyayGuggenheim Securities, LLC
Debjit ChattopadhyayH.C. Wainwright & Co.
Patrick TrucchioH.C. Wainwright & Co.